Please login to the form below

Not currently logged in
Email:
Password:

RA

This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.

Galapagos expands presence in fibrosis, NASH with Evotec deal

Galapagos expands presence in fibrosis, NASH with Evotec deal

The company based in Mechelen, Belgium looks set to break into the big time this year, thanks to its JAK 1 selective inhibitor filgotinib, a new RA treatment co-developed with

Latest news

More from news
Approximately 8 fully matching, plus 142 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).

  • European CTR implementation advances ethical assessment of clinical trials European CTR implementation advances ethical assessment of clinical trials

    Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC

  • Behavioural design - it's a no-brainer Behavioural design - it's a no-brainer

    Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.

  • Deal Watch December 2015 Deal Watch December 2015

    Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics